NCT07303894 A Study of Isoquercetin in People With Ovarian Cancer
| NCT ID | NCT07303894 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Condition | Ovarian Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2026-01-22 |
| Primary Completion | 2032-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 90 participants in total. It began in 2026-01-22 with a primary completion date of 2032-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to test whether isoquercetin can reduce markers in the blood that may indicate the risk of blood clots in people with ovarian cancer. The effects of isoquercetin will be compared with those of a placebo.
Eligibility Criteria
Inclusion Criteria: * Participants must have histological- or cytological-confirmed ovarian cancer (epithelial, serous, or clear cell) and be receiving first-line chemotherapy (day 1 of isoquercetin should align with day 1 of cycle 1 or 2 of chemotherapy) for neoadjuvant, adjuvant, or advanced settings. * Minimum age 18 years * Life expectancy of greater than 6 months. * ECOG performance status \<2 * Participants must have preserved organ and marrow function as defined below: * Platelet count \> 50,000/mcL * Prothrombin time (PT) and partial thromboplastin time (PTT) \< 1.5 x institutional upper limit of normal (ULN) * Total bilirubin \< 3 x ULN without liver metastases and \<5 x ULN in presence of liver metastases. * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 3 X ULN without liver metastases and \<5 x ULN in the presence of liver metastases. * Estimated creatinine clearance (CrCl \>30 ml/min) * The effects of isoquercetin on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Prior history of documented venous thromboembolic event within the last 2 years (excluding central line associated events whereby patients completed anticoagulation) * Active bleeding or high risk for bleeding (e.g., known acute gastrointestinal ulcer) * History of significant hemorrhage (requiring hospitalization or transfusion) outside of a surgical setting within the last 24 months * Familial bleeding diathesis * Known diagnosis of disseminated intravascular coagulation (DIC) * Currently receiving anticoagulant therapy * Current daily use of aspirin, clopidogrel (Plavix), cilostazol (Pletal), aspirin-dipyridamole (Aggrenox) (within 10 days) or considered to use regular use of higher doses of non-steroidal anti-inflammatory agents as determined by the treating physician (e.g ibuprofen \> 800 mg daily or equivalent) * Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Known intolerance of (iso)quercetin, niacin or ascorbic acid (including known G6PD deficiency). * Participants with known brain metastases * Pregnant women are excluded from this study because isoquercetin is a PDI inhibitor with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with isoquercetin, breastfeeding should be discontinued if the mother is treated with isoquercetin.
Contact & Investigator
Jeffrey Zwicker, MD
PRINCIPAL INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Frequently Asked Questions
Who can join the NCT07303894 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Ovarian Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07303894 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07303894 currently recruiting?
Yes, NCT07303894 is actively recruiting participants. Contact the research team at zwickerj@mskcc.org for enrollment information.
Where is the NCT07303894 trial being conducted?
This trial is being conducted at Boston, United States, Basking Ridge, United States, Middletown, United States, Montvale, United States and 4 additional locations.
Who is sponsoring the NCT07303894 clinical trial?
NCT07303894 is sponsored by Memorial Sloan Kettering Cancer Center. The principal investigator is Jeffrey Zwicker, MD at Memorial Sloan Kettering Cancer Center. The trial plans to enroll 90 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.